Foghorn Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Foghorn Therapeutics Inc <FHTX.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Foghorn Therapeutics Inc FHTX.OQ FHTX.O is expected to show a fall in quarterly revenue when it reports results on August 3 (estimated) for the period ending June 30 2026
The Cambridge Massachusetts-based company is expected to report a 20.7% decrease in revenue to $5.995 million from $7.56 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Foghorn Therapeutics Inc is for a loss of 26 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 2.8% in the last three months.
Wall Street's median 12-month price target for Foghorn Therapeutics Inc is $12.00, about 153.2% above its last closing price of $4.74
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.30 | -0.30 | -0.29 | Beat | 4.9 |
Dec. 31 2026 | -0.22 | -0.25 | -0.34 | Missed | -37.4 |
Sep. 30 2025 | -0.31 | -0.33 | -0.25 | Beat | 24.9 |
Jun. 30 2025 | -0.33 | -0.36 | -0.28 | Beat | 21.9 |
Mar. 31 2025 | -0.33 | -0.34 | -0.30 | Beat | 12.3 |
Dec. 31 2024 | -0.27 | -0.33 | -0.30 | Beat | 8.3 |
Sep. 30 2024 | -0.42 | -0.44 | -0.31 | Beat | 29.6 |
Jun. 30 2024 | -0.63 | -0.65 | -0.45 | Beat | 31.3 |
This summary was machine generated July 31 at 13:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)